Lv1
20 积分 2022-12-06 加入
Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma
1天前
待确认
CAR T-cell therapy in autoimmune diseases
3天前
已完结
CAR T therapy beyond cancer: the evolution of a living drug
3天前
已完结
A safe and potent anti-CD19 CAR T cell therapy
3天前
已完结
Infectious Complications in Patients with Hematologic Malignancies Receiving CD19 Vs. BCMA Targeted CAR-T Therapy
9天前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
25天前
已完结
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
1个月前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
1个月前
已完结
The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104
1个月前
已关闭
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
1个月前
已完结
皖公网安备34019202002308
